Cancer diagnostics company to move to innovation district.


Kiyatec, a commercial cancer diagnostics company with ties to Clemson University and Prisma Health, plans to invest $5 million in new offices as the anchor tenant for the city of Greenville's newInnovation District.

Born from technology developed at Clemson University, the company uses functional precision oncology in its diagnostic tool kit, including its first commercial assay, 3D Predict Glioma, for use in glioblastoma and other brain cancer patient care.

The expansion at 2 N. Main St. in Greenville is expected to bring 91 jobs to the area.

"When Kiyatec founder Matt Gevaert came to the Upstate from Canada 25 years ago to study at Clemson, he didn't expect to stay," Mayor Knox White said in a news release. "But like so many successful founders, he discovered you can take an idea from clinical trial to market implementation in Greenville. Our ecosystem supports entrepreneurs. From here you can scale and grow your business. We are pleased that Kiyatec is locating inside the emerging Innovation District in the heart of downtown as they change the world with lifesaving medical advances."

The company established its Clinical Laboratory Improvement Amendments-certified laboratory and began clinical studies in 2015, developing proprietary "ex vivo" 3D cell culture technology platforms to accurately model and predict patient-specific response to approved and investigational cancer drugs targeting a spectrum of solid tumors.


To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT